Current treatments and promising investigations in a multidisciplinary setting

Multidisciplinary clinic care improves adherence to best practice in head and neck cancer

PURPOSE

Multidisciplinary team (MDT) care is widely accepted as best practice for patients with head and neck cancer, although there is little evidence that MDT care improves head and neck cancer related outcomes. This study aims to determine the impact of MDT care on measurable clinical quality indicators (CQIs) associated with improved patient outcomes.

MATERIALS AND METHODS

Patients treated for head and neck cancer at Ipswich Hospital from 2001 to 2008 were identified. Comparisons were made in adherence to CQIs between patients treated before (pre MDT) and after (post MDT) the introduction of the MDT. Associations were tested using the Chi-square and Whitney U-test.

RESULTS

Treatment post MDT was associated with greater adherence to CQIs than pre MDT. Post MDT had higher rates of: dental assessment (59% versus 22%, p<.0001), nutritional assessment (57% versus 39%, p=.015), PET staging (41% versus 2%, p<.0001), chemo-radiotherapy (CRT) for locally advanced disease (66% versus 16%, p<.0001) and use of adjuvant CRT for high risk disease (49% versus 16%, p<.0001). The interval between surgery and radiotherapy was shorter in the post MDT group (p=.009) as was the mean length of hospitalization (p=.002).

CONCLUSIONS

This study highlights the measurable advantages of MDT care over the standard, less formalized, referral process.

Diagnostic accuracy of state-of-the-art MDCT scanners without gantry tilt in patients with oral and oropharyngeal cancer

PURPOSE

Current CT-protocols for staging oral and oropharyngeal cancer include primary transversal slices and secondary tilted slices to avoid artifact-producing regions of dental metalwork. Some of the latest MDCT scanners do not allow gantry tilt. Hence, we assessed the relevance of secondary tilted slices in tumor staging.

MATERIALS AND METHODS

Scans of a tiltable 64-row MDCT-scanner of 82 patients with oral or oropharyngeal cancer were retrospectively and independently evaluated twice by three readers: once using the primary transversal scans only, and once taking the transversal and secondary tilted scans into account. Tumor diameters and TN-stage were determined with both methods. Artifacts on transversal scans were analyzed using a 3-point-ranking-scale.

RESULTS

Image quality was impaired by severe artifacts in 24% of transversal slices of the oral cavity and in 12% of the oropharynx. The three readers detected an average of 57.7 ± 2.1 of 82 tumors (70%) on transversal CT slices. An average of 6.3 ± 0.6 more tumors (8%) were detected when transversal studies were evaluated in conjunction with secondary tilted slices, leading to a significantly (p=0.0156-0.0313) increased average detection rate of 64.0 ± 2.0 tumors (78%). Moreover, secondary tilted slices led to a correction of underestimated tumor stages in up to six patients (7.3%).

CONCLUSION

Tilted slices that avoid artifact-producing regions of dental metalwork significantly improve the reader's sensitivity and are of incremental value for staging of oral and oropharyngeal cancers.

Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response

This study was performed to determine the maximum tolerated dose (MTD) and therapeutic effects of rhenium-186 ((186)Re)-labeled liposomal doxorubicin (Doxil), investigate associated toxicities, and calculate radiation absorbed dose in head and neck tumor xenografts and normal organs. Doxil and control polyethylene glycol (PEG)-liposomes were labeled using (186)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA) method. Tumor-bearing rats received either no therapy (n=6), intravenous Doxil (n=4), or escalating radioactivity of (186)Re-Doxil (185-925 MBq/kg) or (186)Re-PEG-liposomes (1110-1665 MBq/kg) and were monitored for 28 days. Based on body weight loss and systemic toxicity, MTD for (186)Re-Doxil and (186)Re-PEG-liposomes were established at injected radioactivity/body weight of 740 and 1480 MBq/kg, respectively. (186)Re-injected radioactivity/body weight for therapy studies was determined to be 555 MBq/kg for (186)Re-Doxil and 1295 MBq/kg for (186)Re-PEG-liposomes. All groups recovered from their body weight loss, leucopenia, and thrombocytopenia by 28 days postinjection. Normalized radiation absorbed dose to tumor was significantly higher for (186)Re-Doxil (0.299±0.109 Gy/MBq) compared with (186)Re-PEG-liposomes (0.096±0.120 Gy/MBq) (p<0.05). In a separate therapy study, tumor volumes were significantly smaller for (186)Re-Doxil (555 MBq/kg) compared with (186)Re-PEG-liposomes (1295 MBq/kg) (p<0.01) at 42 days postinjection. In conclusion, combination chemoradionuclide therapy with (186)Re-Doxil has promising potential, because good tumor control was achieved with limited associated toxicity.

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

Squamous cell carcinoma of the head and neck (SCCHN) presents at a locally advanced (LA) stage in many patients. Chemotherapy has been successfully integrated into first-line treatment programs, either during or prior to radiotherapy (RT) - the cornerstone modality for local disease control of inoperable disease or when organ preservation is desired. Concomitant chemoradiotherapy (CCRT) provides an absolute survival benefit when compared with other types of locoregional therapy that exclude chemotherapy. Nonetheless, distant metastases still represent the most common cause of treatment failure. Consequently, adding induction chemotherapy (ICT) to definitive non-surgical local therapies with a curative intent has been vigorously explored in LA SCCHN. Recently, it has been shown that ICT using the combination of the taxane docetaxel with cisplatin-5-fluorouracil provides significant survival benefit over cisplatin-5-FU, when used before either definitive RT (TAX323 trial) or carboplatin-based CCRT (TAX324 trial). Docetaxel is also being investigated in metastatic or recurrent (M/R) disease, with promising initial results. It is very likely that the future management strategies of SCCHN will incorporate biologic agents as an add-on to docetaxel-containing schemas, administered either as ICT prior to CCRT in the LA setting or for the management of M/R disease.

Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model

PURPOSE

Positive surgical margins in advanced head and neck squamous cell carcinoma (HNSCC) have a well-documented association with an increased risk of locoregional recurrence and significantly poorer survival. Traditionally, unresectable tumor is treated with postoperative radiotherapy and/or chemotherapy. However, these therapeutic options can delay treatment and increase toxicity. The potential value of intraoperative injection of liposomal therapeutic radionuclides as a locoregional, targeted therapy in unresectable advanced HNSCC was assessed in a nude rat xenograft positive surgical margin model.

EXPERIMENTAL DESIGN

The therapeutic effects of beta-emission rhenium-186 (186Re) carried by liposomes into the tumor remnants in a nude rat squamous cell carcinoma xenograft model were studied. Following the partial resection of tumor xenografts, the animals were intratumorally injected with 186Re-labeled or unlabeled (control) neutrally charged or positively charged 100-nm-diameter liposomes. Tumor size, body weight, hematology, and toxicity were monitored for 35 days posttherapy.

RESULTS

The neutral (n = 4) and cationic (n = 4) liposome control groups showed an increase in tumor growth of 288.0 +/- 37.3% and 292.2 +/- 133.7%, respectively, by day 15. The 186Re-neutral-liposome group (n = 8) and the 186Re-cationic-liposome group (n = 8) presented with an average final tumor volume of 25.6 +/- 21.8% and 28.5 +/- 32.2%, respectively, at the end of the study (day 35). All groups showed consistent increases in body weight. No significant systemic toxicity was observed in any of the animals.

CONCLUSIONS

With excellent tumor suppression and minimal side-effect profile, the intraoperative use of liposomal therapeutic radionuclides may play a role in the management of positive surgical margins in advanced HNSCC.

A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?

PURPOSE OF REVIEW

The aim of this article is to review progress in the treatment of head and neck squamous cell carcinomas (in the light of the most recent literature). Due to the complexity of the disease the multidisciplinary approach needs also a multidisciplinary knowledge which this review tries to summarize.

RECENT FINDINGS

The multidisciplinary treatment approach to the disease includes predictive and prognostic value of biomolecular and clinical factors, the role of induction chemotherapy and concurrent chemo-radiotherapy, new advances in postoperative treatment, treatment-related side-effects and their impact on patients' quality of life, new targeted therapies and treatment choice for incurable patients. Advances in other disciplines, such as radiation therapy and new imaging techniques, will be considered elsewhere in this journal.

SUMMARY

Major advances derived from the strategic use of different treatment and diagnostic modalities. The importance of a multidisciplinary team and knowledge in the approach of this disease should be stressed. Today, a multidisciplinary diagnostic and treatment philosophy is the tool to guarantee the best treatment plan definition, to prevent and relieve treatment adverse effects with the ultimate goal to improve survival.